Susan Mather

Internal Medicine

834 Chestnut St Ste 311
Philadelphia, PA 19107

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Long-term safety of the Pfizer-BioNTech COVID-19 vaccine: Results from the HERO-together study.

Long-term safety of the Pfizer-BioNTech COVID-19 vaccine: Results from the HERO-together study.

Journal: Respiratory medicine

Published: August 29, 2025

The use of observed-to-expected analyses as a signal detection tool in COVID-19 vaccine safety surveillance: lessons learned from an industry perspective.

The use of observed-to-expected analyses as a signal detection tool in COVID-19 vaccine safety surveillance: lessons learned from an industry perspective.

Journal: Frontiers in drug safety and regulation

Published: June 20, 2025

Challenges and Innovations in Pharmacovigilance and Signal Management During the COVID-19 Pandemic: An Industry Perspective.

Challenges and Innovations in Pharmacovigilance and Signal Management During the COVID-19 Pandemic: An Industry Perspective.

Journal: Vaccines

Published: March 04, 2025

Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States.

Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States.

Journal: Vaccine

Published: October 08, 2024

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination.

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination.

Journal: Infectious diseases and therapy

Published: November 13, 2023

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.

Journal: The New England journal of medicine

Published: February 15, 2023

Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.

Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.

Journal: Vaccine

Published: January 10, 2022

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.

Journal: The New England journal of medicine

Published: November 09, 2021

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.

Journal: The New England journal of medicine

Published: September 15, 2021

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

Journal: The New England journal of medicine

Published: May 27, 2021

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Journal: The New England journal of medicine

Published: December 10, 2020

Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.

Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.

Journal: Vaccine

Published: November 16, 2020

Showing 1-12 of 12

Last Updated: 09/26/2026